Valeant Pharmaceuticals International has sweetened its offer to buy Botox maker Allergan for the second time this week.
The Canadian drugmaker said Friday it will now offer $72 and a portion of its stock for each Allergan share. That’s up from an offer of $58.30 and a portion of stock per share that Valeant extended on Wednesday.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
